MitoTALEN reduces mutant mtDNA load and restores tRNA(Ala) levels in a mouse model of heteroplasmic mtDNA mutation.

MitoTALEN reduces mutant mtDNA load and restores tRNA(Ala) levels in a mouse model of heteroplasmic mtDNA mutation.
复制标题

DOI:
10.1038/s41591-018-0166-8
复制
发表时间:
2018-11
期刊:
影响因子:
82.9
通讯作者:
Moraes CT
Moraes CT
中科院分区:
医学1区
文献类型:
--
作者:
Bacman SR;Kauppila JHK;Pereira CV;Nissanka N;Miranda M;Pinto M;Williams SL;Larsson NG;Stewart JB;Moraes CT

文献摘要

参考文献

被引文献

相似文献

线粒体DNA(mtDNA)中的突变是导致几种代谢紊乱的原因,通常涉及肌肉和中枢神经系统。由于mtDNA在氧化磷酸化中的关键作用,大多数致病性mtDNA突变是异质性的,与野生型分子共存。使用具有异质性mtDNA突变的小鼠模型,我们测试了细胞靶向的TALEN(mitoTALEN)是否可以减少肌肉和心脏中的突变mtDNA负荷。通过肌内、静脉内和腹膜内注射施用AAV 9-mitoTALEN。肌肉和心脏被有效地转导,并显示突变mtDNA的稳健减少,其随时间推移而稳定。分子缺陷,即转移RNAAla水平的降低,通过治疗得以恢复。这些结果表明,当在受影响的组织中表达时,mitoTALENs可以逆转小鼠中的疾病相关表型。
Mutations in the mitochondrial DNA (mtDNA) are responsible for several metabolic disorders, commonly involving muscle and the central nervous system. Because of the critical role of mtDNA in oxidative phosphorylation, the majority of pathogenic mtDNA mutations are heteroplasmic, co-existing with wild-type molecules. Using a mouse model with a heteroplasmic mtDNA mutation, we tested whether mitochondrial-targeted TALENs (mitoTALENs) could reduce the mutant mtDNA load in muscle and heart. AAV9-mitoTALEN was administered via intramuscular, intravenous, and intraperitoneal injections. Muscle and heart were efficiently transduced and showed a robust reduction in mutant mtDNA, which was stable over time. The molecular defect, namely a decrease in transfer RNAAla levels, was restored by the treatment. These results showed that mitoTALENs, when expressed in affected tissues, could revert disease-related phenotypes in mice.
DOI: 10.1093/nar/gkw676
发表时间: 2016-09-19
影响因子: 14.9
作者:
Gammage PA;Gaude E;Van Haute L;Rebelo-Guiomar P;Jackson CB;Rorbach J;Pekalski ML;Robinson AJ;Charpentier M;Concordet JP;Frezza C;Minczuk M
通讯作者: Minczuk M
DOI: 10.1038/s41591-018-0165-9
发表时间: 2018-11
期刊: Nature medicine
影响因子: 82.9
作者:
Gammage PA;Viscomi C;Simard ML;Costa ASH;Gaude E;Powell CA;Van Haute L;McCann BJ;Rebelo-Guiomar P;Cerutti R;Zhang L;Rebar EJ;Zeviani M;Frezza C;Stewart JB;Minczuk M
通讯作者: Minczuk M
DOI: 10.1038/mt.2015.126
发表时间: 2015-10-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Hashimoto, Masami;Bacman, Sandra R.;Moraes, Carlos T.
通讯作者: Moraes, Carlos T.
DOI: 10.1093/nar/gkq704
发表时间: 2011-01
影响因子: 14.9
作者:
Li T;Huang S;Jiang WZ;Wright D;Spalding MH;Weeks DP;Yang B
通讯作者: Yang B
DOI: 10.1016/j.febslet.2012.07.043
发表时间: 2012-10-19
期刊: FEBS LETTERS
影响因子: 3.5
作者:
Davies, Stefan M. K.;Sanchez, Maria I. G. Lopez;Filipovska, Aleksandra
通讯作者: Filipovska, Aleksandra